Your request has been received.
We will send you more information as it becomes available.
Effective January 1, 2025: ASP+6% reimbursement for EXPAREL when billing with code J0666 across all outpatient surgical settings.
While opioids have been a mainstay in postsurgical pain control, they are also at the center of an ongoing national crisis. For many patients undergoing surgery, it is their first exposure to opioids.
99% of patients receive opioids to manage
post-surgical pain2*
1 out of 15 surgical patients prescribed an opioid may go
on to long-term use or abuse3,4â€
An estimated 1.1 million Americans will become persistent users of opioids each year following initial exposure after surgery in the hospital3
*In a retrospective study of hospital discharge data (N=37,301).
†In a prospective longitudinal study (N=109).
Hernia
Hysterectomy
Sleeve Gastrectomy
Total Hip
Rotator Cuff
Total Knee
Colectomy
*Newly persistent is defined as a patient using an opioid 3 to 6 months beyond the postsurgical recovery period.
68% of people using pain relievers (non-medically) obtained them from a friend or relative6*
4 out of 5 new heroin users started out by misusing opioids7â€
*According to the 2013 National Survey on Drug Use and Health among past-year users aged ≥ 12 years (N≈37,000).
†From an analysis of the 2008-2010 National Surveys on Drug Use and Health to examine patterns of heroin use and risk behaviors among past-year non-medical users of opioid pain relievers.
~90% of patients said they were concerned about side effects of, addiction to, or dependence on opioids
79% of patients said they preferred a non-opioid pain management option
*From a survey of 500 adults in the United States who had an orthopedic or soft tissue surgery and 200 US surgeons who perform these procedures.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration
This website uses cookies to give you a better browsing experience. By clicking the "Allow all cookies" button, you agree to our use of cookies. For additional information, see our Cookie Notice.